These novel therapies , Tirzepatide , represent a significant advancement in addressing type 2 diabetes and possibly associated ailments . They are categorized as GLP-1 pathway agonists , signifying they to mimic the endogenous GLP-1 substance , stimulating metabolic production and reducing food intake. Despite Tirzepatide each operates largely sim